One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: The aim the study was to calculate remission, recovery and relapse rates in first episode patients with schizophrenia (FES) vs. patients at a later phase (non-FES). Methods: Thirty-two FES and 101 non-FES patients took part in the study. The assessment included testing at baseline and at 1 year with the Positive and Negative Syndrome Scale (PANSS), Calgary Depression scale, State-Trait Anxiety Inventory (STAI), Udvalg for Kliniske Undersøgelser (UKU) scale, Simpson Angus, and General Assessment of Functioning (GAF) subscale. The statistical analysis included chi-square test and analysis of covariance. Results: At baseline 15.62% FES vs. 10.89% non-FES patients were in remission; none of FES vs. 2.97% non-FES patients were in recovery. At endpoint, the respective figures were 12.50% vs. 25.00% and 3.12% vs. 3.96%. None of the differences in rates was significant between the two groups except from the percentage of patients being under medication (higher in the non-FES group). Baseline PANSS negative subscale (PANSS-N) was the only predictor of the outcome at endpoint. Conclusion: The current study reported very low rates of remission and recovery of patients with schizophrenia without any differences between FES and non-FES patients. One possibility is that the increased antipsychotic treatment compensates for the worsening of the illness with time. An accumulating beneficial effect of antipsychotic treatment suggested that early lack of remission is not prognostic of a poor outcome.
Abstract
Objective: The aim the study was to calculate remission, recovery and relapse rates in first episode patients with schizophrenia (FES) vs. patients at a later phase (non-FES). Methods: Thirty-two FES and 101 non-FES patients took part in the study. The assessment included testing at baseline and at 1 year with the Positive and Negative Syndrome Scale (PANSS), Calgary Depression scale, State-Trait Anxiety Inventory (STAI), Udvalg for Kliniske Undersøgelser (UKU) scale, Simpson Angus, and General Assessment of Functioning (GAF) subscale. The statistical analysis included chi-square test and analysis of covariance. Results: At baseline 15.62% FES vs. 10.89% non-FES patients were in remission; none of FES vs. 2.97% non-FES patients were in recovery. At endpoint, the respective figures were 12.50% vs. 25.00% and 3.12% vs. 3.96%. None of the differences in rates was significant between the two groups except from the percentage of patients being under medication (higher in the non-FES group). Baseline PANSS negative subscale (PANSS-N) was the only predictor of the outcome at endpoint. Conclusion: The current study reported very low rates of remission and recovery of patients with schizophrenia without any differences between FES and non-FES patients. One possibility is that the increased antipsychotic treatment compensates for the worsening of the illness with time. An accumulating beneficial effect of antipsychotic treatment suggested that early lack of remission is not prognostic of a poor outcome.
참고문헌 (58)
- Zipursky RB, "Risk of symptom recurrence with medication discontinuation in first-episode psychosis : a systematic review", Schizophr Res, 152, pp.408~414 (2014)
- Lieberman JA, "Prediction of outcome in first-episode schizophrenia", J Clin Psychiatry, 54(Suppl), pp.13~17 (1993)
- Craig TK, "The Lambeth Early Onset(LEO)Team : randomised controlled trial of the effectiveness of specialised care for early psychosis", BMJ, 329, pp.1067~ (2004)
- McGorry P, "Early intervention in psychosis : keeping faith with evidence-based health care", Psychol Med, 40, pp.399~404 (2010)
- Correll CU, "Lower risk for tardive dyskinesia associated with second-generation antipsychotics : a systematic review of 1-year studies", Am J Psychiatry, 161, pp.414~425 (2004)
- Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
- Leucht S, "Second-generation antipsychotics for schizophrenia: can we resolve the conflict?", Psychol Med, 39, pp.1591~1602 (2009)
- Leucht S, "Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials", Schizophr Res, 35, pp.51~68 (1999)
- Leucht S, "How effective are second-generation antipsychotic drugs? A metaanalysis of placebo-controlled trials", Mol Psychiatry, 14, pp.429~447 (2009)
- Haddad PM, "The acute efficacy of antipsychotics in schizophrenia : a review of recent meta-analyses", Ther Adv Psychopharmacol, 8, pp.303~318 (2018)
- Leucht S, "Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : a systematic review and metaanalysis", Lancet, 379, pp.2063~2071 (2012)
- Leucht S, "Maintenance treatment with antipsychotic drugs for schizophrenia", Cochrane Database Syst Rev, (5), pp.CD008016~ (2012)
- Jääskeläinen E, "A systematic review and meta-analysis of recovery in schizophrenia", Schizophr Bull, 39, pp.1296~1306 (2013)
- Menezes NM, "A systematic review of longitudinal outcome studies of first-episode psychosis", Psychol Med, 36, pp.1349~1362 (2006)
- AlAqeel B, "Remission in schizophrenia : critical and systematic review", Harv Rev Psychiatry, 20, pp.281~297 (2012)
- Lally J, "Remission and recovery from first-episode psychosis in adults : systematic review and meta-analysis of long-term outcome studies", Br J Psychiatry, 211, pp.350~358 (2017)
- Fountoulakis KN, "Neurological soft signs significantly differentiate schizophrenia patients from healthy controls", Acta Neuropsychiatr, 30, pp.97~105 (2018)
- Fountoulakis KN, "Neurological soft signs in familial and sporadic schizophrenia", Psychiatry Res, 272, pp.222~229 (2019)
- Fountoulakis KN, "Prevalence and correlates of neurological soft signs in healthy controls without family history of any mental disorder:a neurodevelopmental variation rather than a specific risk factor?", Int J Dev Neurosci, 68, pp.59~65 (2018)
- Fountoulakis KN, "Paternal and maternal age as risk factors for schizophrenia : a case-control study", Int J Psychiatry Clin Pract, 22, pp.170~176 (2018)
- Fountoulakis KN, "The effect of baseline antipsychotic status on the 12-month outcome in initially stabilized patients with schizophrenia", Hum Psychopharmacol, 34, pp.e2712~ (2019)
- Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Addington D, "A depression rating scale for schizophrenics", Schizophr Res, 3, pp.247~251 (1990)
- Addington D, "Reliability and validity of a depression rating scale for schizophrenics", Schizophr Res, 6, pp.201~208 (1992)
- Spielberger CD, "Preliminary manual for the state-trait personality inventory(STPI)" (1979), Universwity of South Florida
- Simpson GM, "A rating scale for extrapyramidal side effects", Acta Psychiatr Scand Suppl, 212, pp.11~19 (1970)
- Lingjaerde O, "The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients", Acta Psychiatr Scand Suppl, 334, pp.1~100 (1987)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders. Text revision" (2000), American Psychiatric Press
- Andreasen NC, "Remission in schizophrenia : proposed criteria and rationale for consensus", Am J Psychiatry, 162, pp.441~449 (2005)
- de Haan L, "Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia", Pharmacopsychiatry, 41, pp.125~128 (2008)
- Kelly DL, "Remission in schizophrenia : the relationship to baseline symptoms and changes in symptom domains during a one-year study", J Psychopharmacol, 23, pp.436~441 (2009)
- Emsley R, "Remission in early psychosis : Rates, predictors, and clinical and functional outcome correlates", Schizophr Res, 89, pp.129~139 (2007)
- Lieberman J, "Time course and biologic correlates of treatment response in first-episode schizophrenia", Arch Gen Psychiatry, 50, pp.369~376 (1993)
- Lally J, "Two distinct patterns of treatment resistance : clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses", Psychol Med, 46, pp.3231~3240 (2016)
- Hegarty JD, "One hundred years of schizophrenia : a meta-analysis of the outcome literature", Schizophr Res, 9, pp.134~ (1993)
- Warner R, "Recovery from schizophrenia and the recovery model", Curr Opin Psychiatry, 22, pp.374~380 (2009)
- Ciudad A, "Remission in schizophrenia : results from a 1-year follow-up observational study", Schizophr Res, 108, pp.214~222 (2009)
- De Hert M, "Remission criteria for schizophrenia : evaluation in a large naturalistic cohort", Schizophr Res, 92, pp.68~73 (2007)
- Chen EY, "Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis : randomised controlled trial", BMJ, 341, pp.c4024~ (2010)
- Boonstra G, "Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients : results from an aborted randomised trial", Int J Psychiatry Clin Pract, 15, pp.128~134 (2011)
- Gaebel W, "Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention : results of a randomized controlled trial within the German Research Network on Schizophrenia", J Clin Psychiatry, 72, pp.205~218 (2011)
- McCreadie RG, "The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group", Acta Psychiatr Scand, 80, pp.597~602 (1989)
- Gardos G, "Are antipsychotic drugs interchangeable?", J Nerv Ment Dis, 159, pp.343~348 (1974)
- Crow TJ, "A randomised controlled trial of prophylactic neuroleptic treatment", Br J Psychiatry, 148, pp.120~127 (1986)
- Takeuchi H, "Antipsychotic treatment for schizophrenia in the maintenance phase : a systematic review of the guidelines and algorithms", Schizophr Res, 134, pp.219~225 (2012)
- Kane JM, "Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia", Arch Gen Psychiatry, 39, pp.70~73 (1982)
- Rabiner CJ, "Outcome study of first-episode psychosis. I: relapse rates after 1 year", Am J Psychiatry, 143, pp.1155~1158 (1986)
- Gitlin M, "Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia", Am J Psychiatry, 158, pp.1835~1842 (2001)
- Uçok A, "One year outcome in first episode schizophrenia. Predictors of relapse", Eur Arch Psychiatry Clin Neurosci, 256, pp.37~43 (2006)
- Cesková E, "One-year follow-up of patients with first-episode schizophrenia(comparison between remitters and non-remitters)", Neuropsychiatr Dis Treat, 3, pp.153~160 (2007)
- Petersen L, "Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample : 2-year follow-up of the OPUS trial", Can J Psychiatry, 53, pp.660~670 (2008)
- Üçok A, "Remission after first-episode schizophrenia : results of a long-term follow-up", Psychiatry Res, 189, pp.33~37 (2011)
- Ceskova E, "Outcome in males with first-episode schizophrenia : 7-year follow-up", World J Biol Psychiatry, 12, pp.66~72 (2011)
- Emsley R, "Remission in first-episode psychosis : predictor variables and symptom improvement patterns", J Clin Psychiatry, 67, pp.1707~1712 (2006)
- Emsley R, "Time course for antipsychotic treatment response in first-episode schizophrenia", Am J Psychiatry, 163, pp.743~745 (2006)
- Addington J, "Symptom remission in first episode patients", Schizophr Res, 106, pp.281~285 (2008)
- Geddes J, "A follow-up study of Northwick Park first episode study subjects", Br J Psychiatry, 165, pp.664~668 (1994)
- Bromet EJ, "Diagnostic shifts during the decade following first admission for psychosis", Am J Psychiatry, 168, pp.1186~1194 (2011)